Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

BackgroundCyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherapy or as combination therapy with an aromatase inhi...

Full description

Bibliographic Details
Main Authors: Sara M. Tolaney, Muralidhar Beeram, J. Thaddeus Beck, Alison Conlin, E. Claire Dees, Shannon L. Puhalla, Brent N. Rexer, Howard A. Burris, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N. Moore, Allison M. Manuel, Andrew Lithio, Gregory L. Price, Sonya C. Chapman, Lacey M. Litchfield, Matthew P. Goetz
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Oncology
Subjects:
abemaciclib
metastatic breast cancer
CDK4
CDK6
endocrine therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.810023/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.810023/full

Similar Items